Trial · NCT04725812
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Latency (in Days) From Enrollment to Delivery | 24 months | 1 enrolled subject withdrew participation before delivery. A second subject withdrew consent after delivery.~Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects. Historical controls were not identified for this terminated study, thus this Outcome Measure cannot be reported. | ||
| SECONDARY | Composite Adverse Maternal Outcomes | 24 months | 1 enrolled subject withdrew participation before delivery. A second subject withdrew consent after delivery.~Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects. Historical controls were not identified for this terminated study, thus this Outcome Measure cannot be reported. | ||
| SECONDARY | Composite Adverse Neonatal Outcomes | 24 months | 1 enrolled subject withdrew participation before delivery. A second subject withdrew consent after delivery. 1 subject's neonate died due to extreme prematurity, which was unrelated to receiving the study drug.~Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects. Historical controls were not identified for this terminated study, thus this Outcome Measure cannot be reported. | ||
| SECONDARY | Changes in Blood and Urine Concentrations of Terminal Complement Protein C5a Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Changes in Blood and Urine Concentrations of Terminal Complement Protein C5b-9 Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Changes in Blood and Urine Concentrations of Complement Protein CD59 Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Aspartate and Alanine Transaminase Concentration Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Hemoglobin Concentration Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Platelet Count Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Lactate Dehydrogenase Concentration Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Serum Creatinine Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Urine Protein Concentration Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Ratio of Urine Protein to Urine Creatinine Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Serum Concentration of Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Serum Concentration of Placental Growth Factor (PlGF) Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Serum Ratio of Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) Concentration to Placental Growth Factor (PlGF) Concentration (sFlt-1/PlGF) Before and After Each Treatment. | 24 months | Assays for research lab samples were not done as the study was prematurely halted. Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects, thus the data could not be reported. | ||
| SECONDARY | Serious Adverse Events | 24 months | 1 enrolled subject withdrew participation before delivery. A second subject withdrew consent after delivery.~Data supporting the primary and secondary outcomes were not collected from the two enrolled subjects. Historical controls were not identified for this terminated study, thus this Outcome Measure cannot be reported. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04725812/outcomes